Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GECKO: MOR106 with Topical Corticosteroids in Atopic Dermatitis
NCT03864627Phase 2Terminated
- Sponsor
- Galapagos NV
- Start
- Mar 2019
- Primary completion
- Feb 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing Placebo + TCS with MOR106 + TCS (2 arms). Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Adverse Event of Special Interest (AESIs), Serious Adverse Events (SAEs). Started Mar 2019; status: terminated.
02
Drugs
MOR106
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03864627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03864627.